Antigenic determinants
A team of researchers at the University of Science and Technology of China has made a breakthrough in designing a highly immunogenic multi-epitope subunit vaccine against the Dugbe virus, a serious tick-borne virus that poses a significant risk to cattle and human health. The innovative immunoinformatic techniques employed in this
European Union
Nigeria and the European Union (EU), along with the Economic Community of West African States (ECOWAS), have signed three major agreements to strengthen local manufacturing, stimulate investment, and promote reproductive health in Nigeria and the West African region. The agreements are part of the EU's Global Gateway Manufacturing
European Union
The Nigerian government has signed three major agreements with the European Union (EU) and the Economic Community of West African States (ECOWAS) to strengthen local manufacturing, stimulate investment, and promote reproductive health in Nigeria and the West African region. The agreements, signed on Thursday at the Nigeria-EU Health Investment Forum
European Union
The Federal Government, in partnership with the European Union (EU) and the Economic Community of West African States (ECOWAS), has signed three landmark agreements to strengthen local manufacturing and stimulate investment across the pharmaceutical ecosystem in Nigeria and West Africa. These agreements, part of the EU Global Gateway Manufacturing and
COVID-19
Researchers from Stanford University School of Medicine have made a breakthrough in vaccine development, demonstrating the effectiveness of computationally designed protein nanoparticle immunogens delivered through messenger RNA (mRNA). The study, which has been peer-reviewed, showcases the potential of combining mRNA vaccines with protein nanoparticle vaccines to elicit strong immune responses.
European Union
The Nigerian government, in partnership with the European Union (EU) and the Economic Community of West African States (ECOWAS), has signed three landmark agreements aimed at strengthening local manufacturing and stimulating investment across the pharmaceutical ecosystem. The agreements, part of the EU's Global Gateway Manufacturing and Access to
European Union
BioNet, a pioneering biotechnology group, has received European Union Good Manufacturing Practice (EU-GMP) certification, a benchmark of pharmaceutical quality and compliance, to produce its acellular pertussis vaccine. This milestone underscores BioNet's dedication to world-class manufacturing standards and marks a key step in the ongoing centralized regulatory review of
COVID-19
Researchers at Chulalongkorn University in Bangkok, Thailand, have conducted a comprehensive study on the genetic diversity and seasonal transmission dynamics of SARS-CoV-2. The study analyzed 8,096 Acute Respiratory Infection (ARI) cases, with 1,152 samples testing positive for SARS-CoV-2, resulting in a positivity rate of 14.2%. The majority
COVID-19
Researchers have found that convalescent plasma and other antibody therapies, including monoclonal antibodies and hyperimmune globulin, can be effective in reducing morbidity and mortality from COVID-19 when administered early in the disease course. According to a recent study, early outpatient convalescent plasma transfusion with high antibody content within 9 days
Bavarian Nordic A/S
The Africa Centres for Disease Control and Prevention (Africa CDC) has strengthened its mpox response with an additional donation of 110,000 doses of mpox vaccines from Bavarian Nordic. The vaccines have been allocated to Uganda through the Mpox Access and Allocation Mechanism (AAM), coordinated by Africa CDC in collaboration
COVID-19
Fresh data on Coronavirus - COVID-19 have been presented in a new report, highlighting the ongoing threat posed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to human health, particularly among immunocompromised and elderly individuals. The emergence of omicron subvariants such as KP.3.1.1 and XEC has been
COVID-19
Research on the coronavirus disease 2019 (COVID-19) pandemic has led to the rapid development of vaccines to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak. Recent studies have focused on understanding the immune response to COVID-19 vaccines in cancer patients undergoing treatment. A new study, published in Human
